JB Chemicals & Pharmaceuticals replies to NSE clarification on Q4 FY2026 results

What JB Chemicals & Pharmaceuticals announced

On 13 June 2026, JB Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM) submitted a reply to a clarification notice issued by the National Stock Exchange (NSE). The NSE had asked the company to provide additional information on its financial results for the quarter ended 31 March 2026, invoking Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company’s response, filed as a PDF attachment, addresses the points raised by the exchange.

Details of the clarification request

The NSE’s clarification notice sought specific disclosures to ensure that the quarterly results complied with the transparency standards mandated by SEBI. While the exact queries are not reproduced in the public summary, they typically cover:

• Consistency of revenue and expense figures with audited statements.
• Clarification of any material variances from prior guidance.
• Confirmation of compliance with accounting standards.

JB Chemicals & Pharmaceuticals confirmed that the figures presented in its quarterly statement are accurate and in line with the audited financials for the period. No amendments to the previously released numbers were indicated.

Key facts at a glance

Why this matters for investors

The filing demonstrates the company’s compliance with SEBI’s disclosure framework, which helps maintain market transparency. By promptly responding to the NSE’s request, JB Chemicals & Pharmaceuticals avoids potential regulatory penalties and reassures investors that its reported numbers have been reviewed and validated. The absence of any revised figures indicates that the originally published quarterly results remain unchanged.

Conclusion

JB Chemicals & Pharmaceuticals has fulfilled the NSE’s clarification requirement under Regulation 33, confirming the accuracy of its Q4 FY2026 financial results. No new financial data were introduced, and the company remains in compliance with listing obligations. Investors can consider the quarterly results as final, pending any future disclosures.